2020
Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes
Quaas AM, Gavrizi SZ, Peck JD, Diamond MP, Legro RS, Robinson RD, Casson P, Christman GM, Zhang H, Hansen KR, Network E. Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes. Fertility And Sterility 2020, 115: 213-220. PMID: 32972733, PMCID: PMC7796980, DOI: 10.1016/j.fertnstert.2020.07.030.Peer-Reviewed Original ResearchConceptsLive birth rateEndometrial thicknessUnexplained infertilityOvarian stimulationRisk ratioLive birthsEMT groupHuman chorionic gonadotropin administrationHigher live birth rateIntrauterine insemination treatmentMean endometrial thicknessMultiple Intrauterine GestationsOvarian stimulation medicationChorionic gonadotropin administrationProspective cohort analysisUnadjusted risk ratioAdjusted risk ratioBirth rateOS-IUIThin endometriumIntrauterine gestationGonadotropin administrationStimulation medicationsClinical trialsTreatment outcomes
2018
Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility
Hansen KR, Eisenberg E, Baker V, Hill MJ, Chen S, Talken S, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Santoro N, Zhang H, Wild RA, Network N. Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2743-2751. PMID: 29767754, PMCID: PMC6276712, DOI: 10.1210/jc.2018-00642.Peer-Reviewed Original ResearchConceptsMidluteal progesterone levelsUnexplained infertilityLive birthsOS-IUIProgesterone levelsPregnancy outcomesClinical trialsTreatment groupsIntrauterine insemination treatmentMultiple Intrauterine GestationsOvarian stimulation medicationSuccessful pregnancy outcomeMulticenter clinical trialLow progesterone levelsMidluteal progesteroneClomiphene citrateOvarian stimulationIntrauterine gestationEndometrial changesPathophysiologic mechanismsGonadotropin treatmentStimulation medicationsProgesterone exposureTreatment outcomesProgesterone concentrationsMajor depression, antidepressant use, and male and female fertility
Evans-Hoeker EA, Eisenberg E, Diamond MP, Legro RS, Alvero R, Coutifaris C, Casson PR, Christman GM, Hansen KR, Zhang H, Santoro N, Steiner AZ, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Ager J, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Lecks K, Martino L, Marunich R, Comfort A, Crow M, Hohmann A, Mallette S, Smith Y, Randolph J, Fisseha S, Ohl D, Ringbloom M, Tang J, Bates W, Mason S, Craig L, Zornes C, Rodriguez M, Hunt T, DiMaria N, Usadi R, Lucidi S, Rhea M, Baker V, Turner K, Brennan M, DelBasso D, Huang H, Jin Y, Li Y, Kuang H, Makuch R, Patrizio P, Sakai L, Scahill L, Song C, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Trussell J, Laylor B, Martinez L, Solnica A, Wojtczuk A, Seungdamrong A, Rosen M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Major depression, antidepressant use, and male and female fertility. Fertility And Sterility 2018, 109: 879-887. PMID: 29778387, PMCID: PMC5973807, DOI: 10.1016/j.fertnstert.2018.01.029.Peer-Reviewed Original ResearchConceptsMaternal major depressionMaternal antidepressant useAntidepressant useLikelihood of pregnancyMale partnersMajor depressionNon-IVF fertility treatmentsFirst trimester pregnancy lossTypes of antidepressantsPHQ-9 scoresFirst trimester miscarriagePatient Health QuestionnairePoor fertility outcomesRisk of miscarriagePoisson regression modelsPPCOS IICohort studyPregnancy outcomesMedication usePrimary outcomeRandomized trialsPregnancy lossHealth QuestionnaireRelative riskTreatment outcomes
2010
Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome
Zhang H, Legro RS, Zhang J, Zhang L, Chen X, Huang H, Casson PR, Schlaff WD, Diamond MP, Krawetz SA, Coutifaris C, Brzyski RG, Christman GM, Santoro N, Eisenberg E. Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. Human Reproduction 2010, 25: 2612-2621. PMID: 20716558, PMCID: PMC2939757, DOI: 10.1093/humrep/deq210.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAndrogensAnovulationBody Mass IndexClomipheneDecision TreesDrug Therapy, CombinationFemaleFertility Agents, FemaleHumansInfertility, FemaleMetforminOrgan SizeOvulation InductionPolycystic Ovary SyndromePregnancyProinsulinRandomized Controlled Trials as TopicSex Hormone-Binding GlobulinTreatment OutcomeWaist-Hip RatioConceptsPolycystic ovary syndromeCombination of CCClomiphene citrateClinical trialsOvarian volumeOvary syndromeOvulation inductionHigher sex hormone-binding globulin levelsSex hormone-binding globulin levelsHormone-binding globulin levelsTreatment effectivenessHigher baseline insulinHip circumference ratioIncidence of ovulationBaseline physical characteristicsBaseline laboratoryOvulatory rateClinical parametersHigher waistBaseline variablesPredictive biomarkersGlobulin levelsCircumference ratioOvulatory responseTreatment outcomes